{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T21:17:14Z","timestamp":1648934234000},"reference-count":58,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.39","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T23:13:54Z","timestamp":1403046834000},"page":"39-47","source":"Crossref","is-referenced-by-count":2,"title":["Hematopoietic Stem Cell Transplantation for Follicular Lymphoma : Optimal Timing and Indication"],"prefix":"10.3960","volume":"54","author":[{"given":"Sung Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Cohen Y, Solal-C&eacute;ligny P, Polliack A: Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88:811-823, 2003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Freedman A: Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol 87:988-995, 2012","DOI":"10.1002\/ajh.23313"},{"key":"3","unstructured":"3 Colombat P, Donadio D, Fouillard L, Milpied N, Tilly H, <I>et al<\/I>.: Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 13:157-162, 1994"},{"key":"4","unstructured":"4 Cervantes F, Shu XO, McGlave PB, Ramsay NK, Miller WJ, <I>et al<\/I>.: Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 16:387-392, 1995"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, <I>et al<\/I>.: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, <I>et al<\/I>.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"7","unstructured":"7 Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, <I>et al<\/I>.: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Brice P, Simon D, Bouabdallah R, B&eacute;langer C, Ha&iuml;oun C, <I>et al<\/I>.: High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11:1585-1590, 2000","DOI":"10.1023\/A:1008399623564"},{"key":"9","unstructured":"9 Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, <I>et al<\/I>.: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97:404-409, 2001"},{"key":"10","unstructured":"10 Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, <I>et al<\/I>.: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22:4926-4933, 2004"},{"key":"11","unstructured":"11 Sebban C, Mounier N, Brousse N, Belanger C, Brice P, <I>et al<\/I>.: Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108:2540-2544, 2006"},{"key":"12","unstructured":"12 Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, <I>et al<\/I>.: Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 21:2324-2331, 2007"},{"key":"13","unstructured":"13 Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, <I>et al<\/I>.: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004"},{"key":"14","unstructured":"14 Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, <I>et al<\/I>.: High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113:995-1001, 2009"},{"key":"15","unstructured":"15 Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, <I>et al<\/I>.: Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013, 2008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, <I>et al<\/I>.: Risk of therapy-related myelodysplastic syndrome\/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 13:450-459, 2002","DOI":"10.1093\/annonc\/mdf109"},{"key":"17","unstructured":"17 Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, <I>et al<\/I>.: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101:2015-2023, 2003"},{"key":"18","unstructured":"18 Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, <I>et al<\/I>.: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25:2554-2559, 2007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, <I>et al<\/I>.: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23:2208-2214, 2005","DOI":"10.1200\/JCO.2005.05.158"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, <I>et al<\/I>.: Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 13:1057-1065, 2007","DOI":"10.1016\/j.bbmt.2007.05.012"},{"key":"21","unstructured":"21 Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, <I>et al<\/I>.: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 14:36-42, 2008"},{"key":"22","unstructured":"22 Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, <I>et al<\/I>.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003"},{"key":"23","unstructured":"23 Kornacker M, Stumm J, Pott C, Dietrich S, S&uuml;ssmilch S, <I>et al<\/I>.: Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20:722-728, 2009"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, <I>et al<\/I>.: Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 96:1128-1135, 2011","DOI":"10.3324\/haematol.2010.030320"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Keeney GE, Gooley TA, Pham RN, Press OW, Pagel JM, <I>et al<\/I>.: The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leuk Lymphoma 48:1961-1967, 2007","DOI":"10.1080\/10428190701583983"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, <I>et al<\/I>.: The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant 40:1039-1044, 2007","DOI":"10.1038\/sj.bmt.1705864"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, <I>et al<\/I>.: Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 19:1331-1335, 2008","DOI":"10.1093\/annonc\/mdn044"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, <I>et al<\/I>.: Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy. J Clin Oncol 28:474s, 2010 [abstract]","DOI":"10.1200\/jco.2010.28.15_suppl.8005"},{"key":"29","unstructured":"29 Brugger W, Hirsch J, Gr&uuml;nebach F, Repp R, Brossart P, <I>et al<\/I>.: Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in folllicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15:1691-1698, 2004"},{"key":"30","unstructured":"30 Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, <I>et al<\/I>.: Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapse follicular lymphoma. Bone Marrow Transplant 43:701-708, 2009"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, <I>et al<\/I>.: A model of <I>in vivo<\/I> purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 34:175-179, 2004","DOI":"10.1038\/sj.bmt.1704551"},{"key":"32","unstructured":"32 Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, <I>et al<\/I>.: Efficacy and safety of high-dose chemotherapy with <I>in vivo<\/I> purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplant 45:1119-1120, 2010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesqui&egrave;res H, <I>et al<\/I>.: <SUP>90<\/SUP>Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk 11:212-218, 2011","DOI":"10.1016\/j.clml.2011.03.007"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, <I>et al<\/I>.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 26:90-95, 2008","DOI":"10.1200\/JCO.2007.11.9248"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, <I>et al<\/I>.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23:461-467, 2005","DOI":"10.1200\/JCO.2005.05.117"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, <I>et al<\/I>.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003","DOI":"10.1182\/blood-2003-04-1205"},{"key":"37","unstructured":"37 van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, <I>et al<\/I>.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Toze CL, Shepherd JD, Connors JM, Voss NJ, Gascoyne RD, <I>et al<\/I>.: Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 25:605-612, 2000","DOI":"10.1038\/sj.bmt.1702191"},{"key":"39","unstructured":"39 Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, <I>et al<\/I>. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003"},{"key":"40","unstructured":"40 Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, <I>et al<\/I>.: Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108:382-389, 2006"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Toze CL, Barnett MJ, Connors JM, Gascoyne RD, Voss NJ, <I>et al<\/I>.: Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 127:311-321, 2004","DOI":"10.1111\/j.1365-2141.2004.05194.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kuruvilla J, Pond G, Tsang R, Gupta V, Lipton JH, <I>et al<\/I>.: Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 14:775-782, 2008","DOI":"10.1016\/j.bbmt.2008.04.007"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ: Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24:1119-1126, 2006","DOI":"10.1200\/JCO.2005.02.7052"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Rizzo JD, Curtis RE, Soci&eacute; G, Sobocinski KA, Gilbert E, <I>et al<\/I>.: Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175-1183, 2009","DOI":"10.1182\/blood-2008-05-158782"},{"key":"45","unstructured":"45 Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, <I>et al<\/I>.: Nonmyeloablative allogeneic transplantation with or without <SUP>90<\/SUP>yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119:6373-6378, 2012"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, <I>et al<\/I>.: Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26:211-217, 2008","DOI":"10.1200\/JCO.2007.11.5477"},{"key":"47","unstructured":"47 Pi&#xF1;ana JL, Martino R, Gayoso J, Sureda A, de la Serna J, <I>et al<\/I>.: Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 95:1176-1182, 2010"},{"key":"48","unstructured":"48 Shea T, Johnson J, Westervelt P, Farag S, McCarty J, <I>et al<\/I>.: Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 17:1395-1403, 2011"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Ono Y, Mori T, Kato J, Yamane A, Shimizu T, <I>et al<\/I>.: Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Am J Hematol 87:929-931, 2012","DOI":"10.1002\/ajh.23261"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, <I>et al<\/I>.: Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or <I>de novo<\/I> diffuse large B-cell lymphoma. Am J Hematol 87:770-775, 2012","DOI":"10.1002\/ajh.23246"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, <I>et al<\/I>.: T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28:3695-3700, 2010","DOI":"10.1200\/JCO.2009.26.9100"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Delgado J, Canals C, Attal M, Thomson K, Campos A, <I>et al<\/I>.: The role of <I>in vivo<\/I> T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 25:551-555, 2011","DOI":"10.1038\/leu.2010.292"},{"key":"53","unstructured":"53 Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, <I>et al<\/I>.: Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 14:236-245, 2008"},{"key":"54","unstructured":"54 Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, <I>et al<\/I>.: Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 147:719-728, 2009"},{"key":"55","unstructured":"55 Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, <I>et al<\/I>.: Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reducedintensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 116:1795-1802, 2010"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, <I>et al<\/I>.: <SUP>90<\/SUP>Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 46:1503-1509, 2011","DOI":"10.1038\/bmt.2010.339"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, <I>et al<\/I>.: Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 18:951-957, 2012","DOI":"10.1016\/j.bbmt.2011.11.028"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Crocchiolo R, Castagna L, F&uuml;rst S, El-Cheikh J, Faucher C, <I>et al<\/I>.: Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 48:249-252, 2013","DOI":"10.1038\/bmt.2012.116"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:53Z","timestamp":1621540013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/1\/54_39\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.39","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}